𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety of biologics in inflammatory bowel disease

✍ Scribed by Wojciech Blonski; Gary R. Lichtenstein

Book ID
107558434
Publisher
Springer
Year
2006
Tongue
English
Weight
602 KB
Volume
9
Category
Article
ISSN
1092-8472

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Therapeutic drug monitoring of biologics
Therapeutic drug monitoring of biologics for inflammatory bowel disease
✍ Jean-FrΓ©dΓ©ric Colombel; Brian G. Feagan; William J. Sandborn; Gert Van Assche; A πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 434 KB πŸ‘ 1 views

## Background: Although tumor necrosis factor (tnf) antagonists are effective for the treatment of crohn's disease and ulcerative colitis, lack and loss of clinical response is a clinical challenge. accordingly, the use of therapeutic drug monitoring has been proposed as a means to optimize treatme

Stopping immunomodulators and biologics
Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
✍ Kofi Clarke; Miguel Regueiro πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop

Safety of immunomodulators and biologics
Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding
✍ Javier P. Gisbert πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 154 KB πŸ‘ 2 views

The aim of this article is to critically review available data regarding the safety of immunomodulators and biological therapies during pregnancy and breast-feeding in women with inflammatory bowel disease. Methotrexate and thalidomide can cause congenital anomalies and are contraindicated during pr